77.16
-0.09(-0.12%)
Currency In USD
Previous Close | 77.25 |
Open | 76.15 |
Day High | 78.16 |
Day Low | 76 |
52-Week High | 86.93 |
52-Week Low | 19.61 |
Volume | 46,784 |
Average Volume | 336,806 |
Market Cap | 1.44B |
PE | -8.41 |
EPS | -9.17 |
Moving Average 50 Days | 73.71 |
Moving Average 200 Days | 57.39 |
Change | -0.09 |
If you invested $1000 in Praxis Precision Medicines, Inc. (PRAX) since IPO date, it would be worth $185.04 as of December 26, 2024 at a share price of $77.16. Whereas If you bought $1000 worth of Praxis Precision Medicines, Inc. (PRAX) shares 3 years ago, it would be worth $261.51 as of December 26, 2024 at a share price of $77.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
GlobeNewswire Inc.
Dec 18, 2024 1:00 PM GMT
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs Praxis plans to i
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
GlobeNewswire Inc.
Dec 03, 2024 1:00 PM GMT
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characte
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
GlobeNewswire Inc.
Nov 26, 2024 1:00 PM GMT
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characte